Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Chronic Heart Failure

  Free Subscription


Articles published in Eur Heart J

Retrieve available abstracts of 221 articles:
HTML format
Text format



Single Articles


    July 2018
  1. VAN EMPEL V, Brunner-La Rocca HP
    Helping to understand heart failure with preserved ejection fraction.
    Eur Heart J. 2018 Jul 9. pii: 5050878. doi: 10.1093.
    PubMed     Text format    


    June 2018
  2. GORTER TM, Obokata M, Reddy YNV, Melenovsky V, et al
    Exercise unmasks distinct pathophysiologic features in heart failure with preserved ejection fraction and pulmonary vascular disease.
    Eur Heart J. 2018 Jun 26. pii: 5045545. doi: 10.1093.
    PubMed     Text format     Abstract available


  3. WEBER T, Chirinos JA
    Pulsatile arterial haemodynamics in heart failure.
    Eur Heart J. 2018 Jun 26. pii: 5045547. doi: 10.1093.
    PubMed     Text format     Abstract available


  4. PACKER M
    Questioning the obvious: does dyspnoea really matter in heart failure?
    Eur Heart J. 2018 Jun 22. pii: 5043114. doi: 10.1093.
    PubMed     Text format    


  5. LAM CSP, Voors AA, de Boer RA, Solomon SD, et al
    Heart failure with preserved ejection fraction: from mechanisms to therapies.
    Eur Heart J. 2018 Jun 13. pii: 5037246. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2018
  6. LUSCHER TF
    Mechanisms and outcomes of heart failure: from HFpEF, HFmrEF, and HFrEF to transplantation.
    Eur Heart J. 2018;39:1749-1753.
    PubMed     Text format    


  7. ANGERMANN CE, Frantz S, Maack C
    The Comprehensive Heart Failure Centre in Wurzburg, Germany.
    Eur Heart J. 2018;39:1757-1760.
    PubMed     Text format    


  8. SWOBODA PP, Plein S
    Heart failure in Diabetic patients.
    Eur Heart J. 2018;39:1755-1757.
    PubMed     Text format    


  9. OBOKATA M, Olson TP, Reddy YNV, Melenovsky V, et al
    Haemodynamics, dyspnoea, and pulmonary reserve in heart failure with preserved ejection fraction.
    Eur Heart J. 2018 May 19. pii: 4999864. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2018
  10. VADUGANATHAN M, Solomon SD
    Expanding the global borders of heart failure: the SHOP and PEOPLE studies.
    Eur Heart J. 2018 Mar 22. pii: 4951580. doi: 10.1093.
    PubMed     Text format    


  11. FONSECA C
    A Heart Failure Clinic.
    Eur Heart J. 2018;39:826-828.
    PubMed     Text format    


  12. BEGGS S, Gardner R
    Thirty years of heart failure.
    Eur Heart J. 2018;39:824-826.
    PubMed     Text format    


    February 2018
  13. EL HARANE N, Kervadec A, Bellamy V, Pidial L, et al
    Acellular therapeutic approach for heart failure: in vitro production of extracellular vesicles from human cardiovascular progenitors.
    Eur Heart J. 2018 Feb 6. pii: 4840711. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2018
  14. LAM CSP, Gamble GD, Ling LH, Sim D, et al
    Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study.
    Eur Heart J. 2018 Jan 29. pii: 4829677. doi: 10.1093.
    PubMed     Text format     Abstract available


  15. NELSON MD, Wei J, Bairey Merz CN
    Coronary microvascular dysfunction and heart failure with preserved ejection fraction as female-pattern cardiovascular disease: the chicken or the egg?
    Eur Heart J. 2018 Jan 16. pii: 4811982. doi: 10.1093.
    PubMed     Text format    


  16. HEINZMANN D, Seizer P
    Mitochondria in heart failure: EMID-sign.
    Eur Heart J. 2018 Jan 3. pii: 4786075. doi: 10.1093.
    PubMed     Text format    


  17. LUND LH, Kober L, Swedberg K, Ruschitzka F, et al
    The year in cardiology 2017: heart failure.
    Eur Heart J. 2018 Jan 2. pii: 4774532. doi: 10.1093.
    PubMed     Text format    


  18. LUSCHER TF
    Heart failure subgroups: HFrEF, HFmrEF, and HFpEF with or without mitral regurgitation.
    Eur Heart J. 2018;39:1-4.
    PubMed     Text format    


  19. PACKER M
    The Future Treatment of Heart Failure?
    Eur Heart J. 2018;39:5-7.
    PubMed     Text format    


    December 2017
  20. TAQUETI VR, Solomon SD, Shah AM, Desai AS, et al
    Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction.
    Eur Heart J. 2017 Dec 26. pii: 4775060. doi: 10.1093.
    PubMed     Text format     Abstract available


  21. ARRIGO M, Vodovar N, Nougue H, Sadoune M, et al
    The heart regulates the endocrine response to heart failure: cardiac contribution to circulating neprilysin.
    Eur Heart J. 2017 Dec 13. pii: 4735305. doi: 10.1093.
    PubMed     Text format     Abstract available


  22. WILCOX JE, Mann DL
    Beta-blockers for the treatment of heart failure with a mid-range ejection fraction: deja-vu all over again?
    Eur Heart J. 2017 Dec 11. pii: 4728646. doi: 10.1093.
    PubMed     Text format    


    November 2017
  23. MASIP J, Peacock WF, Price S, Cullen L, et al
    Indications and practical approach to non-invasive ventilation in acute heart failure.
    Eur Heart J. 2017 Nov 26. pii: 4654494. doi: 10.1093.
    PubMed     Text format     Abstract available


  24. GRASSI G, Mancia G
    'Keep an eye' on the heart: retinal microcirculation disarray in congestive heart failure.
    Eur Heart J. 2017 Nov 23. pii: 4654727. doi: 10.1093.
    PubMed     Text format    


  25. NICHOLLS M
    Finn Waagstein MD PhD: Finn Waagstein reflects on his work and research which saw beta-blockers revolutionise the treatment of heart failure patients. Mark Nicholls reports.
    Eur Heart J. 2017;38:3249-3250.
    PubMed     Text format    


  26. ROSANO GMC
    HFA Congress 2017: The Congress of the Heart Failure Association of the ESC: a continuous success story, the result of a long-term vision.
    Eur Heart J. 2017;38:3042-3043.
    PubMed     Text format    


  27. TOFIELD A
    Heart Failure Congress sets record: The 2017 ESC Heart Failure Association Congress had a new record number of submissions for original science.
    Eur Heart J. 2017;38:3041.
    PubMed     Text format    


    October 2017
  28. NAGELE MP, Barthelmes J, Ludovici V, Cantatore S, et al
    Retinal microvascular dysfunction in heart failure.
    Eur Heart J. 2017 Oct 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  29. CLELAND JGF, Bunting KV, Flather MD, Altman DG, et al
    Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials.
    Eur Heart J. 2017 Oct 10. doi: 10.1093.
    PubMed     Text format     Abstract available


  30. LUSCHER TF
    Special issues in heart failure: pulmonary hypertension, deranged potassium levels, and haemodynamic profiles.
    Eur Heart J. 2017;38:2857-2859.
    PubMed     Text format    


  31. BLANTON RM
    What can haemodynamic profiles teach us about heart failure in the paediatric population?
    Eur Heart J. 2017;38:2910-2911.
    PubMed     Text format    


  32. PITT B, Rossignol P
    Serum potassium in patients with chronic heart failure: once we make a U-turn where should we go?
    Eur Heart J. 2017;38:2897-2899.
    PubMed     Text format    


  33. CHEN S, Dykes JC, McElhinney DB, Gajarski RJ, et al
    Haemodynamic profiles of children with end-stage heart failure.
    Eur Heart J. 2017;38:2900-2909.
    PubMed     Text format     Abstract available


  34. ALDAHL M, Jensen AC, Davidsen L, Eriksen MA, et al
    Associations of serum potassium levels with mortality in chronic heart failure patients.
    Eur Heart J. 2017;38:2890-2896.
    PubMed     Text format     Abstract available


    September 2017
  35. SCHMIEDER RE, Wagner F, Mayr M, Delles C, et al
    The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study.
    Eur Heart J. 2017 Sep 27. doi: 10.1093.
    PubMed     Text format     Abstract available


    August 2017
  36. SZUMMER K, Wallentin L, Lindhagen L, Alfredsson J, et al
    Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014.
    Eur Heart J. 2017 Aug 29. doi: 10.1093.
    PubMed     Text format     Abstract available


  37. FITCHETT D, Butler J, van de Borne P, Zinman B, et al
    Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME(R) trial.
    Eur Heart J. 2017 Aug 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  38. LUSCHER TF
    Update on heart failure: biomarkers, intensive therapy, remote monitoring, and cardiomyocyte renewal.
    Eur Heart J. 2017;38:2315-2317.
    PubMed     Text format    


  39. DE BOER RA, Meems LMG, van Veldhuisen DJ
    Vitamin D supplementation in heart failure: case closed?
    Eur Heart J. 2017;38:2287-2289.
    PubMed     Text format    


    July 2017
  40. GOLIASCH G, Bartko PE, Pavo N, Neuhold S, et al
    Refining the prognostic impact of functional mitral regurgitation in chronic heart failure.
    Eur Heart J. 2017 Jul 25. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2017
  41. LUSCHER TF
    Risk factors for chronic heart failure: obesity, renal dysfunction, arteriovenous fistulas, and amyloid deposition.
    Eur Heart J. 2017;38:1857-1860.
    PubMed     Text format    


  42. ROURA S, Galvez-Monton C, Lupon J, Bayes-Genis A, et al
    Biotherapies and biomarkers for cardiovascular diseases: A 15-year journey at the ICREC (Heart Failure and Cardiac Regeneration) Research Laboratory in Barcelona, Spain.
    Eur Heart J. 2017;38:1784-1786.
    PubMed     Text format    


  43. CHATTERJEE NA, Singh JP
    Making sense of remote monitoring studies in heart failure.
    Eur Heart J. 2017 Jun 13. doi: 10.1093.
    PubMed     Text format    


  44. SUGIHARA S, Burnett JC Jr
    BLAST-AHF: insights into biased AT1 ligands and heart failure. Beginning of the end or end of the beginning?
    Eur Heart J. 2017 Jun 1. doi: 10.1093.
    PubMed     Text format    


    May 2017
  45. MORGAN JM, Kitt S, Gill J, McComb JM, et al
    Remote management of heart failure using implantable electronic devices.
    Eur Heart J. 2017 May 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  46. SCUFFHAM PA, Ball J, Horowitz JD, Wong C, et al
    Standard vs. intensified management of heart failure to reduce healthcare costs: results of a multicentre, randomized controlled trial.
    Eur Heart J. 2017 May 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  47. ZITTERMANN A, Ernst JB, Prokop S, Fuchs U, et al
    Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000 IU vitamin D daily.
    Eur Heart J. 2017 May 12. doi: 10.1093.
    PubMed     Text format     Abstract available


  48. SCHUPKE S, Mehilli J
    Less myocardial scar but greater propensity for heart failure: another gender paradox in myocardial infarction.
    Eur Heart J. 2017 May 5. doi: 10.1093.
    PubMed     Text format    


    April 2017
  49. PANG PS, Butler J, Collins SP, Cotter G, et al
    Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF).
    Eur Heart J. 2017 Apr 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  50. BORLAUG BA, Obokata M
    Is it time to recognize a new phenotype? Heart failure with preserved ejection fraction with pulmonary vascular disease.
    Eur Heart J. 2017 Apr 17. doi: 10.1093.
    PubMed     Text format    


  51. LUSCHER TF
    From systemic and pulmonary hypertension to heart failure: novel drugs and devices.
    Eur Heart J. 2017;38:1087-1090.
    PubMed     Text format    


  52. CLELAND JGF, Mueller C
    What can we learn from SOCRATES: more questions than answers?
    Eur Heart J. 2017;38:1128-1131.
    PubMed     Text format    


  53. MCDIARMID AK, Pellicori P, Cleland JG, Plein S, et al
    Taxonomy of segmental myocardial systolic dysfunction.
    Eur Heart J. 2017;38:942-954.
    PubMed     Text format     Abstract available


    March 2017
  54. PIESKE B, Maggioni AP, Lam CS, Pieske-Kraigher E, et al
    Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.
    Eur Heart J. 2017 Mar 22. doi: 10.1093.
    PubMed     Text format     Abstract available


  55. MCCULLOUGH PA, Rios A, Smith B
    Dialysis fistulas and heart failure.
    Eur Heart J. 2017 Mar 17. doi: 10.1093.
    PubMed     Text format    


  56. OUWERKERK W, Voors AA, Anker SD, Cleland JG, et al
    Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study.
    Eur Heart J. 2017 Mar 11. doi: 10.1093.
    PubMed     Text format     Abstract available


  57. LUSCHER TF
    Frontiers in heart failure: sodium, longitudinal strain, contractility sensor, fatal arrhythmias, and stroke.
    Eur Heart J. 2017;38:693-696.
    PubMed     Text format    


  58. ABDUL-RAHIM AH, Perez AC, MacIsaac RL, Jhund PS, et al
    Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials.
    Eur Heart J. 2017;38:742-750.
    PubMed     Text format     Abstract available


  59. BAX JJ, Delgado V, Sogaard P, Singh JP, et al
    Prognostic implications of left ventricular global longitudinal strain in heart failure patients with narrow QRS complex treated with cardiac resynchronization therapy: a subanalysis of the randomized EchoCRT trial.
    Eur Heart J. 2017;38:720-726.
    PubMed     Text format     Abstract available


    February 2017

  60. Corrigendum to: Sacubitril/valsartan and low blood pressure in heart failure with reduced ejection fraction [Eur Heart J 2017; doi:10.1093/eurheartj/ehx014].
    Eur Heart J. 2017 Feb 28. doi: 10.1093.
    PubMed     Text format    


  61. MULLENS W, Verbrugge FH, Nijst P, Tang WH, et al
    Renal sodium avidity in heart failure: from pathophysiology to treatment strategies.
    Eur Heart J. 2017 Feb 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  62. MATHUR A, Fernandez-Aviles F, Dimmeler S, Hauskeller C, et al
    The consensus of the Task Force of the European Society of Cardiology concerning the clinical investigation of the use of autologous adult stem cells for the treatment of acute myocardial infarction and heart failure: update 2016.
    Eur Heart J. 2017 Feb 15. doi: 10.1093.
    PubMed     Text format    


  63. BAYES-GENIS A, Voors AA, Zannad F, Januzzi JL, et al
    Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action.
    Eur Heart J. 2017 Feb 15. doi: 10.1093.
    PubMed     Text format    


  64. BOHM M, Young R, Jhund PS, Solomon SD, et al
    Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
    Eur Heart J. 2017 Feb 1. doi: 10.1093.
    PubMed     Text format    


  65. SINGH A, Laribi S, Teerlink JR, Mebazaa A, et al
    Agents with vasodilator properties in acute heart failure.
    Eur Heart J. 2017;38:317-325.
    PubMed     Text format    


  66. LUSCHER TF
    An update on heart failure: from experimental findings to clinical trials.
    Eur Heart J. 2017;38:305-307.
    PubMed     Text format    


  67. TOFIELD A
    Teenage weight and risk for adult heart failure.
    Eur Heart J. 2017;38:311-312.
    PubMed     Text format    


  68. TOFIELD A
    End of the road for aliskiren in heart failure.
    Eur Heart J. 2017;38:312-313.
    PubMed     Text format    



  69. Professor Jay Cohn a pioneer in heart failure.
    Eur Heart J. 2017;38:308-309.
    PubMed     Text format    


  70. HARPER AR, Cowie MR
    Remote monitoring for heart failure: the story moves on.
    Eur Heart J. 2017;38:310-311.
    PubMed     Text format    


    January 2017
  71. BRUNO RM, Taddei S
    Sacubril/valsartan and low blood pressure in heart failure with reduced ejection fraction.
    Eur Heart J. 2017 Jan 30. doi: 10.1093.
    PubMed     Text format    


  72. HORCKMANS M, Ring L, Duchene J, Santovito D, et al
    Neutrophils orchestrate post-myocardial infarction healing by polarizing macrophages towards a reparative phenotype.
    Eur Heart J. 2017;38:187-197.
    PubMed     Text format    


  73. LANDIN AM, Hare JM
    The quest for a successful cell-based therapeutic approach for heart failure.
    Eur Heart J. 2017 Jan 10. pii: ehw626. doi: 10.1093.
    PubMed     Text format    


  74. BAVENDIEK U, Aguirre Davila L, Koch A, Bauersachs J, et al
    Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure.
    Eur Heart J. 2017 Jan 8. pii: ehw577. doi: 10.1093.
    PubMed     Text format    


  75. CHATTERJEE NA, Borgquist R, Chang Y, Lewey J, et al
    Increasing sex differences in the use of cardiac resynchronization therapy with or without implantable cardioverter-defibrillator.
    Eur Heart J. 2017 Jan 8. pii: ehw598. doi: 10.1093.
    PubMed     Text format     Abstract available


  76. MAGGIONI AP, Ruschitzka F
    The year in cardiology 2016: heart failure.
    Eur Heart J. 2017 Jan 2. pii: ehw638. doi: 10.1093.
    PubMed     Text format    


    December 2016
  77. MAISEL AS, Di Somma S
    Do we need another heart failure biomarker: focus on soluble suppression of tumorigenicity 2 (sST2).
    Eur Heart J. 2016 Dec 27. pii: ehw462. doi: 10.1093.
    PubMed     Text format    


  78. NAKAMURA T, Masumoto A, Tahara N, Kuroda Y, et al
    Acute heart failure caused by mechanical valve leaflet dislodgment at the mitral position.
    Eur Heart J. 2016 Dec 23. pii: ehw521. doi: 10.1093.
    PubMed     Text format    


  79. BARTUNEK J, Terzic A, Davison BA, Filippatos GS, et al
    Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial.
    Eur Heart J. 2016 Dec 23. pii: ehw543. doi: 10.1093.
    PubMed     Text format     Abstract available


  80. HOEPER MM, Lam CS, Vachiery JL, Bauersachs J, et al
    Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further researchdagger.
    Eur Heart J. 2016 Dec 23. pii: ehw597. doi: 10.1093.
    PubMed     Text format    


  81. MINOIA C, Paolillo S
    Two weeks at Harvard, for two European heart failure trainees.
    Eur Heart J. 2016;37:3553-3554.
    PubMed     Text format    


  82. PAOLILLO S
    The ESC Heart Failure Association postgraduate course in heart failure.
    Eur Heart J. 2016;37:3551-3552.
    PubMed     Text format    


    November 2016
  83. AMMIRATI E, Burns JC, Moreo A, Daniels LB, et al
    Extreme giant aneurysms of three coronary arteries causing heart failure as late sequelae of Kawasaki disease.
    Eur Heart J. 2016.
    PubMed     Text format    



  84. What the Heart Failure Congress means to the Heart Failure Association.
    Eur Heart J. 2016;37:3124-3126.
    PubMed     Text format    



  85. First European advice launched for acute heart failure.
    Eur Heart J. 2016;37:3123-3124.
    PubMed     Text format    



  86. What's new in the European Society of Cardiology 2016 Guidelines for the diagnosis and treatment of acute and chronic heart failure?
    Eur Heart J. 2016;37:3121-3122.
    PubMed     Text format    


    October 2016
  87. CREA F, Bairey Merz CN, Beltrame JF, Kaski JC, et al
    The parallel tales of microvascular angina and heart failure with preserved ejection fraction: a paradigm shift.
    Eur Heart J. 2016.
    PubMed     Text format    


  88. DOCHERTY KF, Campbell RT, Jhund PS, Petrie MC, et al
    How robust are clinical trials in heart failure?
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


    September 2016
  89. JORGE C, Hiltrop N, Desmet W
    Heart failure with preserved ejection fraction: blame the veins....
    Eur Heart J. 2016.
    PubMed     Text format    


  90. MOHSENI H, Kiran A, Khorshidi R, Rahimi K, et al
    Influenza vaccination and risk of hospitalization in patients with heart failure: a self-controlled case series study.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  91. JHUND PS
    Obesity and heart failure: when 'epidemics' collide.
    Eur Heart J. 2016 Sep 22. doi: 10.1093.
    PubMed     Text format    


  92. FRADLEY MG
    The evolving field of cardio-oncology: beyond anthracyclines and heart failure.
    Eur Heart J. 2016;37:2740-2742.
    PubMed     Text format    


  93. ZHABYEYEV P, Oudit GY
    Unravelling the molecular basis for cardiac iron metabolism and deficiency in heart failure.
    Eur Heart J. 2016.
    PubMed     Text format    


  94. KOYAMA M, Yano T, Kikuchi K, Nagahara D, et al
    Lethal heart failure with anti-mitochondrial antibody: an arrhythmogenic right ventricular cardiomyopathy mimetic.
    Eur Heart J. 2016.
    PubMed     Text format    



  95. The Acute Heart Failure Academy.
    Eur Heart J. 2016;37:2568-9.
    PubMed     Text format    


  96. LUSCHER TF
    From heart failure to transplantation: genes, miRNAs, and biomarkers.
    Eur Heart J. 2016;37:2561-3.
    PubMed     Text format    


    August 2016
  97. HADDAD S, Wang Y, Galy B, Korf-Klingebiel M, et al
    Iron-regulatory proteins secure iron availability in cardiomyocytes to prevent heart failure.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  98. LAM CS, Teng TK, Tay WT, Anand I, et al
    Regional and ethnic differences among patients with heart failure in Asia: the Asian sudden cardiac death in heart failure registry.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


    July 2016
  99. ZANNAD F, Ferreira JP
    Globalization of heart failure trials: no turning back on this paradigm.
    Eur Heart J. 2016.
    PubMed     Text format    


  100. LUSCHER TF
    Breaking news in heart failure: ESC Guidelines 2016, non-steroidal mineralocorticoid receptor antagonist, and alternate site CRT pacing.
    Eur Heart J. 2016;37:2085-7.
    PubMed     Text format    


  101. HINDRICKS G, Varma N
    Remote monitoring and heart failure: monitoring parameters, technology, and workflow.
    Eur Heart J. 2016.
    PubMed     Text format    


    June 2016
  102. KRISTENSEN SL, Martinez F, Jhund PS, Arango JL, et al
    Geographic variations in the PARADIGM-HF heart failure trial.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  103. VON ROEDER M, Rommel KP, Blazek S, Daehnert I, et al
    Pressure-volume-loop-guided closure of an iatrogenic atrial septal defect for right heart failure following MitraClip-implantation.
    Eur Heart J. 2016.
    PubMed     Text format    


  104. EPSTEIN M, Pitt BC
    A propitious time for initiating clinical trials in patients with heart failure with reduced ejection fraction and an estimated glomerular filtration rate <30 mL/min with an mineralocorticoid receptor antagonist and a K+ binder: 'the forbidden frui
    Eur Heart J. 2016.
    PubMed     Text format    


  105. BORLAUG BA, Kane GC, Melenovsky V, Olson TP, et al
    Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  106. ROSENGREN A, Aberg M, Robertson J, Waern M, et al
    Body weight in adolescence and long-term risk of early heart failure in adulthood among men in Sweden.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  107. LUSCHER TF
    Frontiers in heart failure: assessement, risk factors, and novel genetic and cell-based therapies.
    Eur Heart J. 2016;37:1629-32.
    PubMed     Text format    


  108. FERREIRA JP, Girerd N, Alshalash S, Konstam MA, et al
    Antithrombotic therapy in heart failure patients with and without atrial fibrillation: update and future challenges.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


    May 2016
  109. PONIKOWSKI P, Voors AA, Anker SD, Bueno H, et al
    2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contributio
    Eur Heart J. 2016.
    PubMed     Text format    


  110. ANTMAN EM, Bax J, Chazal RA, Creager MA, et al
    Updated Clinical Practice Guidelines on Heart Failure: An International Alignment.
    Eur Heart J. 2016.
    PubMed     Text format    


  111. LUSCHER TF
    Frontiers in congenital heart disease: pulmonary hypertension, heart failure, and arrhythmias.
    Eur Heart J. 2016;37:1407-9.
    PubMed     Text format    


    April 2016
  112. NAEGELE M, Hernandez AF, Ruschitzka F
    Finerenone in heart failure: walking a fine line.
    Eur Heart J. 2016.
    PubMed     Text format    


  113. FILIPPATOS G, Anker SD, Bohm M, Gheorghiade M, et al
    A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  114. ARAS MA, Teerlink JR
    Lung ultrasound: a 'B-line' to the prediction of decompensated heart failure.
    Eur Heart J. 2016;37:1252-4.
    PubMed     Text format    


  115. LUSCHER TF
    Imaging as a basis of clinical decision-making in congenital and coronary disease and heart failure.
    Eur Heart J. 2016;37:1171-3.
    PubMed     Text format    


  116. SMISETH OA, Torp H, Opdahl A, Haugaa KH, et al
    Myocardial strain imaging: how useful is it in clinical decision making?
    Eur Heart J. 2016;37:1196-207.
    PubMed     Text format     Abstract available


  117. PATIL NP, Weymann A, Popov AF, Simon AR, et al
    Chest X-ray in cardiac illness: a tale of four decades.
    Eur Heart J. 2016;37:1243.
    PubMed     Text format    


  118. DESAI AS, Jhund PS
    After TOPCAT: What to do now in Heart Failure with Preserved Ejection Fraction.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  119. BAHLS M, Felix SB
    Cachexia and right ventricular dysfunction in chronic heart failure: what is the chicken and what the egg?
    Eur Heart J. 2016.
    PubMed     Text format    


  120. SCHWARZL M, Ojeda F, Zeller T, Seiffert M, et al
    Risk factors for heart failure are associated with alterations of the LV end-diastolic pressure-volume relationship in non-heart failure individuals: data from a large-scale, population-based cohort.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  121. MADONNA R, Van Laake LW, Davidson SM, Engel FB, et al
    Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  122. SCHMIDT M, Lamberts M, Olsen AM, Fosboll E, et al
    Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology.
    Eur Heart J. 2016;37:1015-23.
    PubMed     Text format    


    March 2016
  123. LUSCHER TF
    Update on hypertension: target blood pressure, comorbidities, and outcome.
    Eur Heart J. 2016;37:921-3.
    PubMed     Text format    


  124. BOHM M, Drexler H, Oswald H, Rybak K, et al
    Fluid status telemedicine alerts for heart failure: a randomized controlled trial.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  125. AUER J, Wallner M, Windpessl M, Schmidt WM, et al
    Acute decompensated heart failure associated with a heteroplasmic 3243A>G mitochondrial DNA point mutation.
    Eur Heart J. 2016.
    PubMed     Text format    


  126. BRAUNWALD E
    Academic-industrial collaboration in the development of the first angiotensin receptor blocker: neprilysin inhibitor in the treatment of heart failure.
    Eur Heart J. 2016;37:745-6.
    PubMed     Text format    


    February 2016
  127. HULOT JS, Ishikawa K, Hajjar RJ
    Gene therapy for the treatment of heart failure: promise postponed.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  128. SWEDBERG K, Ryden L
    Treatment of diabetes and heart failure: joint forces.
    Eur Heart J. 2016.
    PubMed     Text format    


  129. LOCH A, Geh DJ, Veriah RS
    Cardiac magnetic resonance imaging: a tool to diagnose parasitic infection?
    Eur Heart J. 2016;37:702.
    PubMed     Text format    


  130. VALENTOVA M, von Haehling S, Bauditz J, Doehner W, et al
    Intestinal congestion and right ventricular dysfunction: a link with appetite loss, inflammation, and cachexia in chronic heart failure.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  131. SINGH A, Laribi S, Teerlink JR, Mebazaa A, et al
    Agents with vasodilator properties in acute heart failure.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  132. LUSCHER TF
    Heart failure and left ventricular remodelling in HFrEF and HFpEF.
    Eur Heart J. 2016;37:423-4.
    PubMed     Text format    


  133. STROMBERG A, Wodlin P
    CardioPulse; Pocket-sized ultrasound for nurses in heart failure?
    Eur Heart J. 2016;37:434-5.
    PubMed     Text format    


  134. TCHAMBAZ L
    CardioPulse: The second Postgraduate Course in Heart Failure: 2016-2017.
    Eur Heart J. 2016;37:430-1.
    PubMed     Text format    


  135. BORLAUG BA
    Defining HFpEF: where do we draw the line?
    Eur Heart J. 2016;37:463-5.
    PubMed     Text format    


  136. DWECK M, Chin C
    CardioPulse: Settling scores with a failing heart.
    Eur Heart J. 2016;37:433-4.
    PubMed     Text format    


  137. WESTENBRINK BD, van Laake LW, Brugts JJ
    CardioPulse: The Postgraduate Course in Heart Failure.
    Eur Heart J. 2016;37:428-9.
    PubMed     Text format    


  138. DIMARCO A, Mansoubi H, Tanner M
    An unusual cause of left ventricular hypertrophy.
    Eur Heart J. 2016;37:497.
    PubMed     Text format    


  139. LECLERCQ C, Sadoul N, Mont L, Defaye P, et al
    Comparison of right ventricular septal pacing and right ventricular apical pacing in patients receiving cardiac resynchronization therapy defibrillators: the SEPTAL CRT Study.
    Eur Heart J. 2016;37:473-83.
    PubMed     Text format     Abstract available


  140. STONE GW, Chung ES, Stancak B, Svendsen JH, et al
    Peri-infarct zone pacing to prevent adverse left ventricular remodelling in patients with large myocardial infarction.
    Eur Heart J. 2016;37:484-93.
    PubMed     Text format     Abstract available


    January 2016
  141. FITCHETT D, Zinman B, Wanner C, Lachin JM, et al
    Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  142. PLATZ E, Lewis EF, Uno H, Peck J, et al
    Detection and prognostic value of pulmonary congestion by lung ultrasound in ambulatory heart failure patientsdagger.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  143. WANG K, Long B, Liu F, Wang JX, et al
    A circular RNA protects the heart from pathological hypertrophy and heart failure by targeting miR-223.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  144. RABER L, Piccolo R
    CardioPulse: Different bleeding scores and which one should we use?
    Eur Heart J. 2016;37:327-31.
    PubMed     Text format    


  145. BUDTS W, Roos-Hesselink J, Radle-Hurst T, Eicken A, et al
    Treatment of heart failure in adult congenital heart disease: a position paper of the Working Group of Grown-Up Congenital Heart Disease and the Heart Failure Association of the European Society of Cardiology.
    Eur Heart J. 2016.
    PubMed     Text format    


  146. NICHOLLS M
    CardioPulse: Cyclosporine to reduce myocardial infarction injury?
    Eur Heart J. 2016;37:210-1.
    PubMed     Text format    


  147. KOMAJDA M, Ruschitzka F
    The year in cardiology 2015: heart failure.
    Eur Heart J. 2016.
    PubMed     Text format    


    December 2015
  148. IUNG B, Doco-Lecompte T, Chocron S, Strady C, et al
    Cardiac surgery during the acute phase of infective endocarditis: discrepancies between European Society of Cardiology guidelines and practices.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  149. HIGASHI H, Inaba S, Izutani H, Sumimoto T, et al
    An unusual cause of life-threatening right-sided heart failure: undifferentiated pleomorphic sarcoma in the right ventricular outflow tract.
    Eur Heart J. 2015.
    PubMed     Text format    


    November 2015
  150. PULS M, Lubos E, Boekstegers P, von Bardeleben RS, et al
    One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  151. OLDENBURG O, Wellmann B, Buchholz A, Bitter T, et al
    Nocturnal hypoxaemia is associated with increased mortality in stable heart failure patients.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  152. LUSCHER TF
    Infections, infarction, and heart failure: prevention and management.
    Eur Heart J. 2015;36:3033-5.
    PubMed     Text format    


  153. MCMURRAY JJ
    Improving outcomes in heart failure: a personal perspectivedagger.
    Eur Heart J. 2015.
    PubMed     Text format    


  154. SKOURI H, Dickstein K
    Heart failure in the Middle East An Emerging Challenge in a Diverse Environment.
    Eur Heart J. 2015;36:2970-2.
    PubMed     Text format    


  155. VAN VELDHUISEN DJ, Ruilope LM, Maisel AS, Damman K, et al
    Biomarkers of renal injury and function: diagnostic, prognostic and therapeutic implications in heart failure.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  156. WANG N, Hung CL, Shin SH, Claggett B, et al
    Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


    October 2015
  157. ROSENKRANZ S, Gibbs JS, Wachter R, De Marco T, et al
    Left ventricular heart failure and pulmonary hypertensiondagger.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  158. KATZ AM, Rolett EL
    Heart failure: when form fails to follow function.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


    September 2015
  159. KOTECHA D, Piccini JP
    Atrial fibrillation in heart failure: what should we do?
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  160. KASTRUP J
    Revival of cytokine therapy in heart failure?
    Eur Heart J. 2015.
    PubMed     Text format    


  161. CIKES M, Solomon SD
    Beyond ejection fraction: an integrative approach for assessment of cardiac structure and function in heart failure.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  162. FRANCIS GS, Thenappan T
    Beta-blockers in heart failure: do we finally have the last word?
    Eur Heart J. 2015.
    PubMed     Text format    


  163. SOLOMON SD, Claggett B, Lewis EF, Desai A, et al
    Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  164. NICHOLLS M
    Research providing new insights into myocardial infarction injury.
    Eur Heart J. 2015;36:2345-6.
    PubMed     Text format    


  165. LUSCHER TF
    Risk factors for and management of heart failure.
    Eur Heart J. 2015;36:2267-9.
    PubMed     Text format    


    August 2015
  166. GORCSAN J 3RD, Sogaard P, Bax JJ, Singh JP, et al
    Association of persistent or worsened echocardiographic dyssynchrony with unfavourable clinical outcomes in heart failure patients with narrow QRS width: a subgroup analysis of the EchoCRT trial.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  167. MALASA M, Werner N, Nickenig G, Hammerstingl C, et al
    Transcatheter tricuspid valve repair in a patient with isolated functional tricuspid valve regurgitation.
    Eur Heart J. 2015.
    PubMed     Text format    


  168. GORCSAN J 3RD, Schwartzman D
    Ventricular arrhythmias after cardiac resynchronization therapy: does reverse remodelling reverse risk?
    Eur Heart J. 2015.
    PubMed     Text format    


  169. LUSCHER TF
    Prevention of non-communicable diseases and special causes of heart failure.
    Eur Heart J. 2015;36:2019-2022.
    PubMed     Text format    


  170. CHATTERJEE NA, Roka A, Lubitz SA, Gold MR, et al
    Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  171. LUSCHER TF
    Novel aspects of heart failure: from combined neurohormal blockade to embryonic stem cells.
    Eur Heart J. 2015;36:1937-9.
    PubMed     Text format    


  172. TAYLOR J
    Depression associated with five-fold increased mortality risk in heart failure patients.
    Eur Heart J. 2015;36:1946.
    PubMed     Text format    


  173. TAYLOR J
    Cognitive impairment predicts worse outcome in heart failure.
    Eur Heart J. 2015;36:1945.
    PubMed     Text format    


  174. TOFIELD A
    Digoxin mortality in heart failure and atrial fibrillation.
    Eur Heart J. 2015;36:1944-5.
    PubMed     Text format    


  175. PERRONE-FILARDI P, Paolillo S, Costanzo P, Savarese G, et al
    The role of metabolic syndrome in heart failure.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


    July 2015
  176. GONZALEZ-LOPEZ E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, et al
    Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  177. CASTANO A, Bokhari S, Maurer MS
    Unveiling wild-type transthyretin cardiac amyloidosis as a significant and potentially modifiable cause of heart failure with preserved ejection fraction.
    Eur Heart J. 2015.
    PubMed     Text format    


  178. CORRADO D, Wichter T, Link MS, Hauer R, et al
    Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement.
    Eur Heart J. 2015.
    PubMed     Text format    


  179. DICKSTEIN K
    Is substantial renal dysfunction in patients with heart failure no longer a contraindication for RAS inhibition? The power of a large, high-quality registry to illuminate major clinical issues.
    Eur Heart J. 2015.
    PubMed     Text format    


  180. HOENDERMIS ES, Liu LC, Hummel YM, van der Meer P, et al
    Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  181. BORLAUG BA
    Taking aim at pulmonary hypertension in heart failure with preserved ejection fraction.
    Eur Heart J. 2015.
    PubMed     Text format    


  182. STONE GW, Adams DH, Abraham WT, Kappetein AP, et al
    Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions: A consensus document from the Mitral Valve Academic Research Consortium.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  183. GUO J, Mihic A, Wu J, Zhang Y, et al
    Canopy 2 attenuates the transition from compensatory hypertrophy to dilated heart failure in hypertrophic cardiomyopathy.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  184. MUNZEL T, Gori T, Keaney JF Jr, Maack C, et al
    Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


    June 2015
  185. FADINI GP, Avogaro A, Degli Esposti L, Russo P, et al
    Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  186. TOFIELD A
    Blood sugar levels in heart failure patients predict risk of early death, hospitalizations, and diabetes.
    Eur Heart J. 2015;36:1498-9.
    PubMed     Text format    


  187. GIRERD N, Collier T, Pocock S, Krum H, et al
    Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  188. FELKER GM
    Augmenting outcomes in patients with advanced heart failure.
    Eur Heart J. 2015.
    PubMed     Text format    


  189. YSSAP J, Lebreton G, Hoen B, Larifla L, et al
    Infected left ventricular thrombus revealing an unrecognized coronary dissection after blunt chest trauma, treated with emergency heart transplantation.
    Eur Heart J. 2015.
    PubMed     Text format    


  190. PARKER JD
    Therapeutic developments in the therapy of heart failure: lessons to be learned.
    Eur Heart J. 2015.
    PubMed     Text format    


  191. ANKER SD, Coats AJ, Cristian G, Dragomir D, et al
    A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial).
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  192. FANKHAUSER CD, Nietlispach F, Emmert MY, Maisano F, et al
    Antegrade valve embolization after transcatheter treatment for pure aortic regurgitation.
    Eur Heart J. 2015.
    PubMed     Text format    


  193. LUSCHER TF
    Heart failure and comorbidities: renal failure, diabetes, atrial fibrillation, and inflammation.
    Eur Heart J. 2015;36:1415-7.
    PubMed     Text format    


  194. EDNER M, Benson L, Dahlstrom U, Lund LH, et al
    Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  195. CHUNG ES, Miller L, Patel AN, Anderson RD, et al
    Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  196. AMSTEIN R, Luscher TF, Maisano F, Ruschitzka FT, et al
    The new postgraduate course in heart failure (PCHF): update on 1st PCHF and announcement of the 2nd PCHF. A project of the European Society of Cardiology Heart Failure Association, the ESC European Heart Academy, the Zurich Heart House and the Univers
    Eur Heart J. 2015;36:1354-5.
    PubMed     Text format    


    May 2015
  197. DESAI AS, McMurray JJ, Packer M, Swedberg K, et al
    Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  198. MEBAZAA A, Yilmaz MB, Levy P, Ponikowski P, et al
    Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Em
    Eur Heart J. 2015.
    PubMed     Text format    


  199. MENASCHE P, Vanneaux V, Hagege A, Bel A, et al
    Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  200. FLORAS JS, Ponikowski P
    The sympathetic/parasympathetic imbalance in heart failure with reduced ejection fraction.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  201. SLIWA K, Johnson MR, Zilla P, Roos-Hesselink JW, et al
    Management of valvular disease in pregnancy: a global perspective.
    Eur Heart J. 2015;36:1078-89.
    PubMed     Text format     Abstract available


  202. HILFIKER-KLEINER D, Haghikia A, Nonhoff J, Bauersachs J, et al
    Peripartum cardiomyopathy: current management and future perspectives.
    Eur Heart J. 2015;36:1090-7.
    PubMed     Text format     Abstract available


  203. BUCKLEY U, Shivkumar K
    Implantable cardioverter defibrillators: even better than we thought?
    Eur Heart J. 2015.
    PubMed     Text format    


    April 2015
  204. RAPHAEL CE, Finegold JA, Barron AJ, Whinnett ZI, et al
    The effect of duration of follow-up and presence of competing risk on lifespan-gain from implantable cardioverter defibrillator therapy: who benefits the most?
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  205. SOLOMON S, Goncalves A
    CardioPulse: drinking moderate amounts of alcohol is linked to reduced risk of heart failure.
    Eur Heart J. 2015;36:890-1.
    PubMed     Text format    


  206. CONEN D
    Alcohol consumption and incident cardiovascular disease: not just one unifying hypothesis.
    Eur Heart J. 2015;36:897-8.
    PubMed     Text format    



  207. Stem cells for heart failure: the experience of writing a Cochrane systematic review.
    Eur Heart J. 2015;36:834-6.
    PubMed     Text format    


  208. HILFIKER-KLEINER D, Westhoff-Bleck M, Gunter HH, von Kaisenberg CS, et al
    A management algorithm for acute heart failure in pregnancy. The Hannover experience.
    Eur Heart J. 2015;36:769-70.
    PubMed     Text format    


    March 2015
  209. AMINZADEH MA, Tseliou E, Sun B, Cheng K, et al
    Therapeutic efficacy of cardiosphere-derived cells in a transgenic mouse model of non-ischaemic dilated cardiomyopathy.
    Eur Heart J. 2015;36:751-62.
    PubMed     Text format     Abstract available


  210. SAVVATIS K, Schultheiss HP, Tschope C
    Endomyocardial biopsy and ultrastructural changes in dilated cardiomyopathy: taking a 'deeper' look into patients' prognosis.
    Eur Heart J. 2015;36:708-10.
    PubMed     Text format    


  211. NABETA T, Itatani K, Miyaji K, Ako J, et al
    Vortex flow energy loss reflects therapeutic effect in dilated cardiomyopathy.
    Eur Heart J. 2015;36:637.
    PubMed     Text format    


    February 2015
  212. CALIFF RM
    LCZ696: too good to be true?
    Eur Heart J. 2015;36:410-2.
    PubMed     Text format    


  213. LUBITZ SA, Singh JP
    Biventricular pacing: more is better!
    Eur Heart J. 2015;36:407-9.
    PubMed     Text format    


    January 2015
  214. BANYPERSAD SM, Fontana M, Maestrini V, Sado DM, et al
    T1 mapping and survival in systemic light-chain amyloidosis.
    Eur Heart J. 2015;36:244-51.
    PubMed     Text format     Abstract available


    September 2014
  215. MIZIA-STEC K, Wybraniec MT, Bochenek T, Gierlaszynska K, et al
    Fulminant variant of Loeffler disease mimicking arrhythmogenic right ventricular cardiomyopathy in the course of enterobiasis.
    Eur Heart J. 2014.
    PubMed     Text format    


  216. CLAEYS MJ
    High-sensitivity troponin: does it predict the shape of the iceberg underneath the surface?
    Eur Heart J. 2014;35:2273-5.
    PubMed     Text format    


  217. KAYE GC, Linker NJ, Marwick TH, Pollock L, et al
    Effect of right ventricular pacing lead site on left ventricular function in patients with high-grade atrioventricular block: results of the Protect-Pace study.
    Eur Heart J. 2014.
    PubMed     Text format     Abstract available


    August 2014
  218. FERRARI R, Rizzo P
    The Notch pathway: a novel target for myocardial remodelling therapy?
    Eur Heart J. 2014;35:2140-5.
    PubMed     Text format     Abstract available


  219. NENSA F, Poeppel TD, Krings P, Schlosser T, et al
    Multiparametric assessment of myocarditis using simultaneous positron emission tomography/magnetic resonance imaging.
    Eur Heart J. 2014;35:2173.
    PubMed     Text format    


  220. RUWALD AC, Kutyifa V, Ruwald MH, Solomon S, et al
    The association between biventricular pacing and cardiac resynchronization therapy-defibrillator efficacy when compared with implantable cardioverter defibrillator on outcomes and reverse remodelling.
    Eur Heart J. 2014.
    PubMed     Text format     Abstract available


    May 2014
  221. CHIN CW, Shah AS, McAllister DA, Joanna Cowell S, et al
    High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis.
    Eur Heart J. 2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Chronic Heart Failure is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: